Depression Side Effects Found In Puberty Blockers Being Pushed To Children

( There is sufficient evidence to suggest that puberty blockers cause depression.

A 2020 research team was the first to employ an animal model to evaluate these medications’ possible neurological and psychological consequences.

Twenty-two years after physicians started giving gender dysphoric teenagers puberty-blocking medications on an experimental basis, they found that leuprolide therapy raised sadness in female mice and had “profound impacts” on male mice’s stress levels and interest in female mice.

Leuprolide is a medicine used to prevent puberty. It’s also the “medicine” known as “chemical castration.”

The study revealed that chronic leuprolide treatment, starting after the onset of puberty, exerts gender-specific effects on social preference, despondency-like behavior, hyponeophagia, neuroendocrine responses to mild stress, and hyperactivity of the [dentate gyrus], a crucial neurobiological regulator of stress responses in mice.”

According to the research, leuprolide therapy resulted in gender-specific behavioral abnormalities in male and female mice. For instance, the puberty suppression medication changed the social preferences of male mice but not those of female mice. The experimental group of male mice exhibited “a lack of interest in females and demonstrated no aggressive behavior against other male mice,” in contrast to the control group of mice, who preferred the company of female mice.

Leuprolide-treated female mice had lower hunger and increased immobility, two hallmarks of depressive-like behavior in animal models. The increased neural activity in the female mice’s “mood and anxiety control, stress resistance, and cognition” area of the brain confirmed the findings concerning their depressive behavior.

Leuprolide (GnRH agonists) suppression of puberty as an intervention for childhood gender dysphoria was first used in 1998 by Dutch doctors, who later published two papers on the topic. The controversial “Dutch protocol,” as it came to be known, was later adopted by the United States and serves as the cornerstone of the “gender-affirming” model of care, which makes use of puberty inhibitors, hormones intended for different genders, and surgical procedures to “affirm” minors’ choice of transgender identity.

According to internist and researcher Dr. Claudia Gennari, the unfavorable mental consequences discovered in this study have significant implications for pediatric gender medicine.

A pediatric endocrinologist at Boston Children’s Hospital’s GeMS (Gender Management Service), which was the first clinic in the US to start giving puberty blockers to youngsters, claims that they are handed out to children “like candy” to a “skyrocketing” number of new patients.